News Medical on MSN13d
Study finds no clinical advantage of budesonide inhaler over fluticasone in COPD
A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
Transpire Bio Announces Progress in Clinical Development with Initiation of a New Human Subject Study for Asthma and COPD Inhaled Drug Program
Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...
thecardiologyadvisor.com4d
In COPD, CV Events Increase With Use of Single-Inhaler Triple Therapy
Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.
HealthDay on MSN9d
Study Compares Single-Inhaler Triple Therapies for Treatment of COPD
For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
The Financial Express7h
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
Commonly prescribed medications can increase fall risk and related injuries in people with COPD
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...
Monthly Prescribing Reference13d
Study Compares Single-Inhaler Triple Therapies for Treatment of COPD
a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...
AARP2d
15 Costly Medicare Drugs Selected for Next Round of Price Negotiations
Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...
Pharmaceutical Technology2d
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.
News Medical on MSN4d
The impact of fall-risk medications on injuries in COPD patients
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...